2seventy bio, Inc.

2seventy bio, Inc. operates as a biotechnology company focused on the development and commercialization of oncology cell therapies. The company develops and commercializes cell therapies for oncology, with a primary focus on Abecma (idecabtagene vicleucel) for multiple myeloma, in partnership with Bristol Myers Squibb. It participates in co-development, co-promotion, and profit-sharing agreements for Abecma and provides support for its commercial success in the United States. The company also offers resources and information for patients, families, and care partners affected by multiple myeloma. The company was founded in 2021 and is based in Cambridge, Massachusetts. 2seventy bio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.